NSG6005 IFinal IQuestions
The IU.S. IFood Iand IDrug IAdministration I(FDA) Iregulates:
The Iofficial Ilabeling Ifor Iall Iprescriptions Iand Iover-the-counter Idrugs
Nurse Ipractitioner Iprescriptive Iauthority Iis Iregulated Iby:
The IState IBoard Iof INursing Ifor Ieach Istate
Electronic Ihealth Irecords I(EHRs)
Allow Ifor Iall Ipatient Idata Ito Ibe Icentralized Iin Ione Ilocation Ifor Iaccess Iby Imultiple Iproviders
Alterations Iin Idrug Imetabolism Iamong IAsians Imay Ilead Ito
Slower Imetabolism Iof Iantidepressants, Irequiring Ilower Idoses
Pharmacokinetics Iamong IAsians Iare Iuniversal Ito Iall Ithe IAsian Iethnic Igroups.
B. I I I I I I I IFalse
Gender Idifferences Ibetween Imen Iand Iwomen Iin Ipharmacokinetics Iinclude:
Higher Iproportion Iof Ibody Ifat Iso Ithat Ilipophilic Idrugs Ihave Irelatively Igreater Ivolumes Iof
Idistribution
The Ifactor Ithat Ihas Ithe Igreatest Ieffect Ion Imales Ideveloping Imale Isexual Icharacteristics Iis:
Androgen Iproduction
An Iadvantage Iof Iprescribing Ia Isublingual Imedication Iis Ithat Ithe Imedication Iis:
A. Absorbed Irapidly
Infants Iand Iyoung Ichildren Iare Iat Ihigher Irisk Iof IADRs Idue Ito:
B. Lack Iof Isafety Iand Iefficacy Istudies Iin Ithe Ipediatric Ipopulation
Pharmacokinetic Ifactors Ithat Iaffect Iprescribing Iinclude:
C. IBioavailability
Carbamazepine Ihas Ia IBlack IBox Iwarning Irecommending Itesting Ifor Ithe IHLA-B*1502 Iallele Iin
Ipatients Iwith IAsian Iancestry Iprior Ito Istarting Itherapy Idue Ito:
C. I I I I I I I IIncreased Irisk Ifor IStevens-Johnson Isyndrome Iin IAsian Ipatients Iwith IHLA-B*1502 Iallele
Genetic Ipolymorphisms Iaccount Ifor Idifferences Iin Imetabolism, Iincluding:
D. I I I I I I I IAll Iof Ithe Iabove
A Ipatient Imay Idevelop Ineutropenia Ifrom Iusing Itopical ISilvadene Ifor Iburns. INeutropenia Iis Ia(n):
A. I I I I I I I ICytotoxic Ihypersensitivity Ireaction
The Ielderly Iare Iat Ihigh Irisk Iof IADRs Idue Ito:
D. I I I I I I I IAge-related Idecrease Iin Irenal Ifunction
, The Itime Irequired Ifor Ithe Iamount Iof Idrug Iin Ithe Ibody Ito Idecrease Iby I50% Iis Icalled:
Half-life
The Iangiotensin Iconverting Ienzyme I(ACE) Iinhibitor Ilisinopril Iis Ia Iknown Iteratogen. ITeratogens
Icause IType I____ IADR
D
Common IOTC Ipain Irelievers Isuch Ias Iacetaminophen Ior Iibuprofen:
Are Iharmful Iif Itaken Iin Ihigher Ithan Irecommended Iamounts
A Ipatient’s Inutritional Iintake Iand Ilab Iwork Ireflect Ihypoalbuminemia. IThis Iis Icritical Ito
Iprescribing Ibecause:
Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected
Warfarin Iresistance Imay Ibe Iseen Iin Ipatients Iwith IVCORC1 Imutation, Ileading Ito:
Decreased Iresponse Ito Iwarfarin
The Ifirst Istep Iin Ithe Iprescribing Iprocess Iaccording Ito Ithe IWorld IHealth IOrganization Iis:
C.
Diagnosing Ithe Ipatient’s Iproblem
A Inurse Ipractitioner Iwould Iprescribe Ithe Iliquid Iform Iof Iibuprofen Ifor Ia Isix-year-old Ibecause:
A Isix-year-old Imay Ihave Iproblems Iswallowing Ia Ipill
The Ipoint Iin Itime Ion Ithe Idrug Iconcentration Icurve Ithat Iindicates Ithe Ifirst Isign Iof Ia Itherapeutic
Ieffect Iis Ithe:
C
Onset Iof IAction
When Iobtaining Ia Idrug Ihistory Ifrom IHarold, Ihe Igives Iyou Ia Icomplete Ilist Iof Ihis Iprescription
Imedications. IHe Idenies Itaking Iany Iother Idrugs, Ibut Iyou Ifind Ithat Ihe Ioccasionally Itakes Iaspirin Ifor
Ihis Iarthritis Iflare-ups. IThis Iis Ian Iexample Iof
A Icommon Imisconception Ithat Iintermittently Itaken IOTC Imedications Iare Inot Ian Iimportant Ipart Iof
Ihis Idrug Ihistory
Which Ione Iof Ithe Ifollowing Istatements Iabout Ibioavailability Iis Itrue?
*Bioavailability Iissues Iare Iespecially Iimportant Ifor Idrugs Iwith Inarrow Itherapeutic Iranges
Ior Isustained Irelease Imechanisms I
All Ibrands Iof Ia Idrug Ihave Ithe Isame Ibioavailability I
Drugs Ithat Iare Iadministered Imore Ithan Ionce Ia Iday Ihave Ia Igreater Ibioavailability Ithan Idrugs Igiven
Ionce Idaily I
Combining Ian Iactive Idrug Iwith Ian Iinert Isubstance Idoes Inot Iaffect Ibioavailability
Beta Iblockers Itreat Ihypertension Ibecause Ithey:
Reduce Iperipheral Iresistance
Which Iof Ithe Ifollowing Iis Itrue Iabout Iprocainamide Iand Iits Idosing Ischedule?
The IU.S. IFood Iand IDrug IAdministration I(FDA) Iregulates:
The Iofficial Ilabeling Ifor Iall Iprescriptions Iand Iover-the-counter Idrugs
Nurse Ipractitioner Iprescriptive Iauthority Iis Iregulated Iby:
The IState IBoard Iof INursing Ifor Ieach Istate
Electronic Ihealth Irecords I(EHRs)
Allow Ifor Iall Ipatient Idata Ito Ibe Icentralized Iin Ione Ilocation Ifor Iaccess Iby Imultiple Iproviders
Alterations Iin Idrug Imetabolism Iamong IAsians Imay Ilead Ito
Slower Imetabolism Iof Iantidepressants, Irequiring Ilower Idoses
Pharmacokinetics Iamong IAsians Iare Iuniversal Ito Iall Ithe IAsian Iethnic Igroups.
B. I I I I I I I IFalse
Gender Idifferences Ibetween Imen Iand Iwomen Iin Ipharmacokinetics Iinclude:
Higher Iproportion Iof Ibody Ifat Iso Ithat Ilipophilic Idrugs Ihave Irelatively Igreater Ivolumes Iof
Idistribution
The Ifactor Ithat Ihas Ithe Igreatest Ieffect Ion Imales Ideveloping Imale Isexual Icharacteristics Iis:
Androgen Iproduction
An Iadvantage Iof Iprescribing Ia Isublingual Imedication Iis Ithat Ithe Imedication Iis:
A. Absorbed Irapidly
Infants Iand Iyoung Ichildren Iare Iat Ihigher Irisk Iof IADRs Idue Ito:
B. Lack Iof Isafety Iand Iefficacy Istudies Iin Ithe Ipediatric Ipopulation
Pharmacokinetic Ifactors Ithat Iaffect Iprescribing Iinclude:
C. IBioavailability
Carbamazepine Ihas Ia IBlack IBox Iwarning Irecommending Itesting Ifor Ithe IHLA-B*1502 Iallele Iin
Ipatients Iwith IAsian Iancestry Iprior Ito Istarting Itherapy Idue Ito:
C. I I I I I I I IIncreased Irisk Ifor IStevens-Johnson Isyndrome Iin IAsian Ipatients Iwith IHLA-B*1502 Iallele
Genetic Ipolymorphisms Iaccount Ifor Idifferences Iin Imetabolism, Iincluding:
D. I I I I I I I IAll Iof Ithe Iabove
A Ipatient Imay Idevelop Ineutropenia Ifrom Iusing Itopical ISilvadene Ifor Iburns. INeutropenia Iis Ia(n):
A. I I I I I I I ICytotoxic Ihypersensitivity Ireaction
The Ielderly Iare Iat Ihigh Irisk Iof IADRs Idue Ito:
D. I I I I I I I IAge-related Idecrease Iin Irenal Ifunction
, The Itime Irequired Ifor Ithe Iamount Iof Idrug Iin Ithe Ibody Ito Idecrease Iby I50% Iis Icalled:
Half-life
The Iangiotensin Iconverting Ienzyme I(ACE) Iinhibitor Ilisinopril Iis Ia Iknown Iteratogen. ITeratogens
Icause IType I____ IADR
D
Common IOTC Ipain Irelievers Isuch Ias Iacetaminophen Ior Iibuprofen:
Are Iharmful Iif Itaken Iin Ihigher Ithan Irecommended Iamounts
A Ipatient’s Inutritional Iintake Iand Ilab Iwork Ireflect Ihypoalbuminemia. IThis Iis Icritical Ito
Iprescribing Ibecause:
Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected
Warfarin Iresistance Imay Ibe Iseen Iin Ipatients Iwith IVCORC1 Imutation, Ileading Ito:
Decreased Iresponse Ito Iwarfarin
The Ifirst Istep Iin Ithe Iprescribing Iprocess Iaccording Ito Ithe IWorld IHealth IOrganization Iis:
C.
Diagnosing Ithe Ipatient’s Iproblem
A Inurse Ipractitioner Iwould Iprescribe Ithe Iliquid Iform Iof Iibuprofen Ifor Ia Isix-year-old Ibecause:
A Isix-year-old Imay Ihave Iproblems Iswallowing Ia Ipill
The Ipoint Iin Itime Ion Ithe Idrug Iconcentration Icurve Ithat Iindicates Ithe Ifirst Isign Iof Ia Itherapeutic
Ieffect Iis Ithe:
C
Onset Iof IAction
When Iobtaining Ia Idrug Ihistory Ifrom IHarold, Ihe Igives Iyou Ia Icomplete Ilist Iof Ihis Iprescription
Imedications. IHe Idenies Itaking Iany Iother Idrugs, Ibut Iyou Ifind Ithat Ihe Ioccasionally Itakes Iaspirin Ifor
Ihis Iarthritis Iflare-ups. IThis Iis Ian Iexample Iof
A Icommon Imisconception Ithat Iintermittently Itaken IOTC Imedications Iare Inot Ian Iimportant Ipart Iof
Ihis Idrug Ihistory
Which Ione Iof Ithe Ifollowing Istatements Iabout Ibioavailability Iis Itrue?
*Bioavailability Iissues Iare Iespecially Iimportant Ifor Idrugs Iwith Inarrow Itherapeutic Iranges
Ior Isustained Irelease Imechanisms I
All Ibrands Iof Ia Idrug Ihave Ithe Isame Ibioavailability I
Drugs Ithat Iare Iadministered Imore Ithan Ionce Ia Iday Ihave Ia Igreater Ibioavailability Ithan Idrugs Igiven
Ionce Idaily I
Combining Ian Iactive Idrug Iwith Ian Iinert Isubstance Idoes Inot Iaffect Ibioavailability
Beta Iblockers Itreat Ihypertension Ibecause Ithey:
Reduce Iperipheral Iresistance
Which Iof Ithe Ifollowing Iis Itrue Iabout Iprocainamide Iand Iits Idosing Ischedule?
